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Background
One of the most significant differences in proteins pro-
duced in eukaryotes is their chemical modification, which
does not occur in prokaryotes. These post-translational
modifications of certain amino acid residues are often
essential for protein function. Therefore, generating sys-
tems that allow them to be made in bacterially expressed
proteins is of great fundamental interest and of potential
benefit in biotechnological applications. We have devel-
oped a system that allows the production of one kind of
protein modification in bacteria, N-terminal acetylation
[1], by coexpressing the yeast NatB acetylation complex
and the target protein tropomyosin (TM).
Results
Tropomyosin is a protein that plays a role both in control-
ling the contraction of muscle and also a much more gen-
eral role as part of the scaffolding matrix within cells,
known as the actin cytoskeleton. Without an essential
acetylation of one of its ends, TM no longer binds to the
cytoskeleton and the cells are severely impaired or even
die. A pair of proteins, of which similar versions are found
in all eukaryotic cells, does this modification. In yeast,
these proteins are Nat3 (195 amino acids) and Mdm20
(796 aa), together making up the NatB acetylation com-
plex [2]. Nat3 is the acetylase core, and Mdm20 the TM
binding protein. Yeast and mammalian TM can be easily
overproduced in bacteria. However, since bacteria do not
have proteins similar to NatB, TM does not work correctly
when produced in this way. We generated an E. coli coex-
pression system for TM plus the two NatB components
based on the Novagen pET Duet vectors that allow clon-
ing of two genes in tandem under identical T7 promoters.
The coding regions of the two proteins were cloned
directly from S. cerevisiae genomic DNA via PCR. Expres-
sion trials of these proteins in isolation showed good
overproduction of Nat3, with a clear band visible in total
cell lysate separated by SDS-PAGE. This band has an
apparent size of around 28 kDa, somewhat larger than the
predicted molecular mass of 22.9 kDa. However, no band
was visible for Mdm20 at around its predicted 92.8 kDa.
The two coding sequences were then transferred into the
Duet expression vector, and the resulting vector was trans-
formed into E. coli BL21(DE3)pLys. For TM coexpression,
the cells were additionally transformed with pJC20
expression vectors containing either yeast TM1 or verte-
brate skeletal TM that we had characterized previously [3-
5]. Vectors were maintained by selection by ampicillin
(pJC20) plus either kanamycin (pRSFDuet) or spectino-
mycin (pCDFDuet). TM was purified and its binding to
rabbit F-actin measured by cosedimentation studies as
described [3]. The yeast TM1 species was found to behave
similar to the one carrying a short N-terminal extension,
such as Ala-Ser, or Ala-Gly-Ser-Ser-Ser, to mimic the
acetylation present in native TM from eukaryotic sources,
thus indicating the presence of N-terminal acetylation as
a prerequisite for high-affinity binding of TM to actin.
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Our data show that all three proteins can be produced via
coexpression. However, since their relative quantities
proved to be very variable, more work is needed to opti-
mize the expression conditions to produce balanced
quantities of the acetylating proteins (Nat3/Mdm20) and
a larger amount of the acetylation target (TM).
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